NCT04774315View on ClinicalTrials.gov

Molecular Endotypes of Chronic Idiopathic Urticaria

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Chronic Urticaria, Idiopathic
Interventions
DRUG

Omalizumab

omalizumab 300mg SQ every 4 weeks as part of standard of care

Trial Locations (1)

80045

University of Colorado Anschutz, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER